AbbVie's ALTITUDE trial of RGX-314 gene therapy for diabetic retinopathy marked completedNov 16Trial updateAbbVieREGENXBIO Inc.
AbbVie registers Phase 1 PK study of trosunilimab given IV and SC in healthy adultsNov 13Weekly roundup, 8 itemsABBV-295ABBV-722
AbbVie lifts 2026 EPS guidance, closes Apogee deal, posts Skyrizi and Juvmo approvalsNov 12M&AAbbVieBiovie Inc.Updated
Genmab's Phase 3 China DLBCL trial of epcoritamab posts results, listed active not recruitingNov 10Trial updateAbbVieepcoritamab-bysp
FDA record shows earlier accelerated nod for mirvetuximab soravtansine-gynx, date unclearNov 9Regulatory decisionAbbViemirvetuximab soravtansineUpdated
AbbVie posts updates on three early-stage trials: obesity, drug interaction, glabellar linesNov 6Weekly roundup, 5 itemsABBV-295AbbVieUpdated
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Genmab's EPCORE DLBCL-1 Phase 3 trial posts results after primary completion in October 2026Nov 3Trial updateAbbVieepcoritamab-bysp
AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studiesOct 29Weekly roundup, 7 itemsABBV-706ABBV-722Updated
FDA approves efficacy supplement for AbbVie's SkyriziOct 23Regulatory decisionAbbVierisankizumab-rzaa
AbbVie posts results for Japan CLL/SLL study; also files new Phase 3 NSCLC trial vs pembrolizumabOct 23Weekly roundup, 6 itemsABBV-1480AbbVieUpdated
AbbVie terminates Phase 1b liver cancer trial of livmoniplimab plus budigalimab in ChinaOct 21Trial updateAbbViebudigalimab
AbbVie's CANASA label update and ABBV-253 trial recruitment lead busy week of registry changesOct 16Weekly roundup, 9 itemsABBV-1042ABBV-253Updated
AbbVie's AGN-151586 Phase 2 forehead lines study completes enrollment; four more trials registeredOct 8Weekly roundup, 5 itemsAbbVieAGN-151586Updated
AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
ADARx Pharmaceuticals closes IPO and AbbVie private placementSep 28FinancingAbbVieADARx Pharmaceuticals, Inc.